RE104 is a proprietary, potential best-in-class, patented prodrug of 4-OH-DiPT, which is administered via a single subcutaneous injection. Reunion designed RE104 to deliver a short, acute psychoactive ...
FDA approves first brain stimulation device for home depression treatment. Flow Neuroscience's FL-100 headset uses electrical ...
Bodybuilding Bros on MSN
How regular exercise affects depression according to Cochrane Review
The research published in the Cochrane Library, Neuroscience & Biobehavioral Reviews revealed that when it comes to ...
Exercise is as effective as psychological therapy and taking antidepressants for alleviating symptoms of depression. | ...
On Tuesday, Alto Neuroscience, Inc. (NASDAQ:ANRO) announced an asset purchase agreement with Chase Therapeutics Corporation for a portfolio of dopamine agonist drug combinations for ...
The MarketWatch News Department was not involved in the creation of this content. -- Successful outcome from recent FDA meeting guides Alto's plan to accelerate development of ALTO-207, with capital ...
Alto Neuroscience receives US patent for ALTO-207; strengthens IP portfolio for patients with treatment-resistant depression: Mountain View, California Saturday, January 17, 2026, ...
The company believes that, together with previously issued patents and pending applications in the U.S. and internationally, the ALTO-207 intellectual property portfolio provides protection extending ...
Almost half of people with depression meet criteria for being ‘treatment-resistant’, found a new study published in the British Journal of Psychiatry. Definitions for treatment-resistant depression ...
In a major shift for how mental health conditions might be treated, the US Food and Drug Administration (FDA) has approved the first at-home brain-stimulation device to treat moderate to severe major ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback